Skip to main content
main-content

Ross Camidge MD, PhD

Dr Camidge is the Director of Thoracic Oncology at the University of Colorado. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). Dr Camidge joined the University of Colorado as a visiting Professor in November of 2005, and was recruited as full-time faculty in October of 2007. He is dual-trained in both medical oncology and clinical pharmacology. In 2012 he was announced as the recipient of the Bonnie J. Addario International Lectureship Award as a ‘Luminary in the quest to eradicate lung cancer’. In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today’. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession’. In 2015, he became the inaugural holder of the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center and in 2016, the Lung Cancer Foundation presented him with the Breath Away From The Cure Award describing him as ‘Simply one of the best in treating lung cancer today’.

Dr Camidge is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) and a member of the National Comprehensive Cancer Network Lung Cancer Committee.

Dr Camidge has been principal investigator on numerous clinical trials in early phase drug development and thoracic malignancies. He has authored more than 150 articles and reviews in peer-reviewed journals such as Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology and The New England Journal of Medicine. He has presented his research at multiple national and international scientific meetings.

Latest contributions from Ross Camidge

02-10-2019 | Non-small-cell lung cancer | Video | Article

Expert highlights: Lung and thoracic cancers at ESMO 2019

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

08-09-2019 | Lung cancer | Video | Article

Expert highlights from WCLC 2019

WATCH | Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

11-06-2019 | Non-small-cell lung cancer | ASCO 2019 | News

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

01-06-2019 | Lung cancer | ASCO 2019 | Article

Expert highlights: Lung cancer at ASCO 2019

Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).